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Introduction
Glial cell line–derived neurotrophic factor (GDNF), neurturin 
(NRTN), artemin (ARTN), and persephin (PSPN) are secreted 
growth  factors  collectively  known  as  GDNF  family  ligands 
(GFLs). GFLs play a pivotal role in differentiation and mainte-
nance of the nervous system and, in the case of GDNF, in kid-
ney development and spermatogenesis (Bespalov and Saarma, 
2007). GFLs have pharmaceutical potential for the treatment   
of neurological diseases. In particular, GDNF has shown very 
promising results in two Parkinson’s disease clinical trials   
(Gill  et  al.,  2003;  Slevin  et  al.,  2005),  although  a  larger   
placebo-controlled study failed to show clear clinical benefits   
of GDNF (Lang et al., 2006). GDNF is also a potent survival 
factor for central motoneurons and may have a clinical potential   
in the treatment of amyotrophic lateral sclerosis (Henderson   
et al., 1994).
The conventional receptor complex for soluble GFLs con-
sists of a ligand-specific glycosylphosphatidylinositol (GPI)- 
anchored coreceptor, GDNF family receptor  (GFR-), and a 
signal-transducing module, the receptor tyrosine kinase RET, or, 
in some cells, neural cell adhesion molecule (NCAM; Paratcha   
et al., 2003). GDNF activates either RET or NCAM via GFR-1, 
NRTN via GFR-2, ARTN via GFR-3, and PSPN uses GFR-4. 
Notably, GDNF promotes differentiation and tangential migration 
of  embryonic  cortical  -aminobutyric  acid  (GABA)–releasing 
(GABAergic) neurons that lack both RET and NCAM (Pozas and 
Ibáñez,  2005). An  unknown  receptor  may  thus  mediate  some 
GDNF-dependent processes in cortical development.
Growth  factor  signaling  is  critically  modulated  by  the 
ECM. The activities of many growth factors are affected by   
G
lial cell line–derived neurotrophic factor (GDNF) 
family ligands (GFLs) are potent survival factors 
for  dopaminergic  neurons  and  motoneurons 
with therapeutic potential for Parkinson’s disease. Soluble 
GFLs bind to a ligand-specific glycosylphosphatidylinositol-
anchored coreceptor (GDNF family receptor ) and sig-
nal through the receptor tyrosine kinase RET. In this paper, 
we show that all immobilized matrix-bound GFLs, except 
persephin, use a fundamentally different receptor. They 
interact with syndecan-3, a transmembrane heparan sul-
fate (HS) proteoglycan, by binding to its HS chains with 
high affinity. GFL–syndecan-3 interaction mediates both 
cell spreading and neurite outgrowth with the involvement 
of  Src  kinase  activation.  GDNF  promotes  migration  of 
cortical neurons in a syndecan-3–dependent manner, and 
in agreement, mice lacking syndecan-3 or GDNF have a 
reduced number of cortical -aminobutyric acid–releasing 
neurons, suggesting a central role for the two molecules   
in cortical development. Collectively, syndecan-3 may di-
rectly transduce GFL signals or serve as a coreceptor,   
presenting GFLs to the signaling receptor RET.
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Structural  specificity  of  the  heparin–GDNF  interaction 
was studied by SPR using desulfated heparins. Specific removal 
of 2-O-sulfate, 6-O-sulfate, and N-sulfate groups from heparin 
significantly impaired the interaction with GDNF, as determined 
by  both  competition  assays  with  heparin  and  direct  binding   
to GDNF (Fig. S1). Our results support the earlier observation   
that 2-O-sulfation is crucial for GDNF interaction with hepa-
rin (Rickard et al., 2003; Rider, 2003), although in our assays, 
6-O- and N-sulfation were also important.
To test whether heparin-binding GFLs would bind to nat-
ural HSPGs, we used SPR to assay the direct interaction be-
tween  immobilized  GFLs  and  the  HS-carrying  extracellular 
domain of syndecan-3 purified from rat brain (Raulo et al., 
1994). The Kds for GDNF, NRTN, and ARTN were in the   
10–50-nM range (Fig. 2 A), indicating high affinity binding to 
syndecan-3 and supporting the notion that these GFLs could di-
rectly interact with HSPGs at the cell surface and/or in the 
ECM. The binding occurs specifically via HS chains because 
heparinase III treatment strongly inhibited the interaction of 
GDNF and syndecan-3 (Fig. 2 B). For PSPN dynamics, data 
could not be fit with a simple curve, and because of limiting 
concentrations of syndecan-3, Kd was only estimated to be   
>70 nM. Thus, it appears that PSPN binds syndecan-3 with 
much lower affinity than the rest of the GFLs (Fig. 2 A).
The interaction between GDNF and syndecan-3 in a cellu-
lar context was studied by chemical cross-linking and by Förster 
resonance  energy  transfer  (FRET).  Chemical  cross-linking  of 
125I-GDNF to C6 cells, a rat glioma cell line, which expresses 
syndecan-3 (Kinnunen et al., 1998), followed by immunoprecipi-
tation with syndecan-3 antibodies revealed a specific interaction 
of GDNF and syndecan-3 on the cell surface (Fig. 2 B). A high 
molecular weight complex visualized by autoradiography repre-
sents the GDNF complex with a syndecan-3 oligomer. The inter-
action was displaced by an excess of unlabeled (cold) GDNF   
or HB-GAM, another syndecan-3–specific ligand. Addition of   
1 µg/ml heparin or removing HS chains by heparinase III treatment 
abolished 
125I-GDNF binding to syndecan-3 almost completely 
(Fig. 2 B), confirming the involvement of HS chains in the inter-
action. To exclude the possibility of GPI-anchored GFR-1 in-
volvement in the GDNF interaction with syndecan-3 on the cell 
surface, we treated C6 cells with phosphatidylinositol-specific 
PLC (PI-PLC). This treatment had no significant effect on   
125I-GDNF binding to syndecan-3, indicating that GFR-1 is not 
required for the GDNF–syndecan-3 complex formation. In addi-
tion, the data on PI-PLC treatment indicate that the cell surface 
GPI-linked HSPGs, glypicans, are not involved in the interaction.
To study the effects of GDNF on syndecan-3 localization, 
human embryonic kidney cells were transiently transfected with 
syndecan-3, which was C-terminally fused with CFP or YFP 
(Hienola et al., 2006). GDNF induced a rapid syndecan-3 oligo-
merization on the plasma membrane, as determined from an   
increase in FRET between the two fluorophores (Fig. 2 D). Col-
lectively,  these  results  allowed  us  to  conclude  that  GDNF, 
ARTN, and NRTN, but not PSPN, bind heparin and syndecan-3 
with high affinity and that interaction between GDNF and HS 
chains of syndecan-3 on the cell surface triggers the proteo-
glycan oligomerization.
interaction with ECM heparan sulfates (HSs) presented by HS 
proteoglycans (HSPGs). In addition, cell surface HSPGs, in partic-
ular syndecans, act as coreceptors for many growth factors and 
adhesion molecules (Bernfield et al., 1999; Bishop et al., 2007). 
A member of the family, syndecan-3 (neuronal syndecan or   
N-syndecan), is a signal-transducing receptor for ECM-located 
heparin-binding growth-associated molecule (HB-GAM; also 
known  as  pleiotrophin;  Raulo  et  al.,  1994;  Kinnunen  et  al., 
1998). HB-GAM binding to HS chains of syndecan-3 activates 
Src family kinases (SFKs), leading to hippocampal neurite out-
growth and neuronal migration (Kinnunen et al., 1998; Rauvala 
et al., 2000; Hienola et al., 2006). Interestingly, only immobilized 
HB-GAM can trigger this biological response via syndecan-3, 
whereas free (soluble) HB-GAM acts as an inhibitor (Raulo   
et al., 1994; Kinnunen et al., 1998).
GDNF was originally purified by heparin affinity chroma-
tography (Lin et al., 1993) and has later been shown to interact 
with HS (Rickard et al., 2003). HSs are required for GDNF sig-
naling through the GFR-1–RET complex (Barnett et al., 2002; 
Parkash et al., 2008). Recently, ARTN and NRTN interaction 
with heparin was demonstrated (Silvian et al., 2006; Alfano   
et al., 2007). Almost nothing is known about the interaction of 
PSPN with heparin, and the molecular identity of HSPGs that 
bind GFLs has remained obscure.
In the present study, we elucidate heparin and HS binding 
to the individual members of the GFL family. We find that   
syndecan-3 acts as a functional receptor for immobilized GDNF, 
triggering cell spreading and neurite outgrowth via SFK activa-
tion. Our migration assays implicate GDNF–syndecan-3 signal-
ing in the regulation of brain cortex development. The results 
suggest a dual mode of action for GDNF, namely signaling   
via conventional receptors, such as RET or NCAM, in a free 
form, whereas immobilized matrix-bound GDNF would signal 
through syndecan-3.
Results
GDNF, NRTN, and ARTN interact with 
heparin and HSPG syndecan-3
We first asked whether all GFLs bind heparin and what struc-
tural determinants of heparin are required for this interaction. 
Putative heparin binding sites (Cardin and Weintraub, 1989; 
Hileman et al., 1998) are present in the primary structure of GDNF, 
NRTN, and ARTN but not in PSPN. In agreement, 
125I-labeled 
GDNF, NRTN, and ARTN bind to the heparin–Sepharose col-
umn (Fig. 1 A), whereas PSPN does not. The affinity of GFLs 
for heparin and HS was measured by surface plasmon resonance 
(SPR), implementing dynamics and an equilibrium response. 
The dissociation constants (Kds) for GDNF, NRTN, and ARTN 
were  all  between  10  and  50  nM,  with  the  exception  of  the   
dynamics-derived Kd for NRTN, which was >100 nM. PSPN 
had three orders of magnitude lower affinity for heparin than the 
other ligands; the Kd was 29.1 µM (dynamics) or 11.1 µM (equi-
librium; Table S1 and Fig. 1 B). The affinity of 
3H-labeled 
heparin for GDNF was confirmed using a third independent 
method, scintillation proximity assay (Leppänen et al., 2004), 
yielding a similar Kd (10 nM; unpublished data).155 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
Intriguingly, the ability of GFLs to interact with HSPGs raises 
the question of whether GFLs are bound to ECM in the tissue 
and, if so, whether this affects their biological activity.
To answer the first question, we used juvenile kidney and 
brain, in which GDNF is relatively abundant and can be read-
ily detected. We performed biochemical fractionation of juve-
nile  mice  tissues  followed  by  Western  blotting.  We  found 
GDNF in the ECM fraction of the postnatal brain and kidney 
(Fig. 2 C). Lower amounts of GDNF were associated with the 
GDNF localization in the ECM and  
GFL-induced cell spreading
Immobilized  and  diffusible  molecules  differentially  regulate 
neuronal development and maintenance. It is generally thought 
that most neurotrophic factors, including GFLs, act as diffusible 
soluble proteins. In contrast, the ECM molecule HB-GAM signals 
through syndecan-3 only as an immobilized matrix-bound protein 
and is not active as a soluble (diffusible) protein at physiologi-
cal concentrations (Raulo et al., 1994; Kinnunen et al., 1998). 
Figure 1.  GFL binding to heparin. (A) Elution of 
125I-GFLs from a heparin–Sepharose column by a step-wise NaCl gradient. PSPN elutes at a 0.5-M NaCl 
concentration, indicating a very weak interaction with heparin. GDNF elutes from the heparin column at a 0.75–1-M NaCl concentration, ARTN elutes at 
a 1–1.5-M NaCl concentration, and NRTN elutes at a 1.5-M NaCl concentration. (B) Heparin binding to immobilized GFLs was followed by SPR using 
the IAsys optical biosensor. The Kds were determined from dynamics as well as equilibrium data (insets), and their values are indicated in the graphs. Error 
bars show SEM from three to four experiments for each condition. Kon is the association rate constant. arcsec, arcsecond.JCB • VOLUME 192 • NUMBER 1 • 2011   156
Figure 2.  GDNF, NRTN, and ARTN bind directly to syndecan-3 with high affinity. (A) Syndecan-3 (S3) binding to GFLs, immobilized on the cuvette, was 
followed by SPR. The Kds were determined from dynamics as well as equilibrium data (insets), and their values are indicated in the graphs. Error bars show 
SEM from three to four experiments for each condition. Kon is the association rate. arcsec, arcsecond. conc, concentration. (B) GDNF interacts directly with 157 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
To further confirm the involvement of HSPG, we gener-
ated a GDNF mutant that lacks 38 N-terminal amino acids   
(N-GDNF) and does not bind to heparin (Fig. S2 C; Alfano   
et al., 2007). The N-terminal deletion does not significantly affect 
the ability of soluble N-GDNF to activate the conventional 
GFR-1–RET receptor complex but may have weaker affinity 
to GFR-1 when expressed in the absence of RET (Fig. S2 A; 
Eketjäll et al., 1999). Soluble N-GDNF mutant was also shown 
to  be  biologically  active  (Fig.  S2  B)  in  previously  reported 
GFR-–RET-mediated neurite outgrowth assays on dorsal root 
ganglia neurons (Paveliev et al., 2004). This GDNF variant also 
stimulates MAPK signaling and promotes survival of dopa-
minergic neurons in vivo (Piltonen et al., 2009). However, im-
mobilized N-GDNF failed to induce attachment and spreading   
of SHEP cells (Fig. 3 D), indicating a requirement for HS inter-
action with immobilized GDNF. These results suggest that GDNF 
has two modes of action: as a diffusible free protein activating 
GFR-1–RET receptors and as an immobilized matrix-bound 
protein activating the signaling complex based on HSPG. Thus, 
HSPGs may serve as coreceptors for GFLs and/or deliver the 
growth factors to GFR-1 or NCAM receptors.
GDNF interaction with HSPGs is required 
for Src kinase activation
Immobilized GDNF induces activation of SFKs in SHEP cells 
that is HSPG dependent, as it is abolished by heparinase III 
treatment and does not occur on N-GDNF (Fig. 3 E). In addi-
tion, SFK activation may not depend on GFR-1, as suggested 
by the lack of signaling inhibition by PI-PLC treatment (Fig. 3 E). 
Pretreatment  of  SHEP  cells  with  the  selective  and  nontoxic   
SFK inhibitor SU6656 (Paveliev et al., 2004) diminished their 
spreading on immobilized GDNF (Fig. 3 F) but did not impair 
their adherence. Similar results were obtained with cells infected 
with a dominant-negative Src kinase adenovirus (Fig. 3 G), sug-
gesting that SFK activation is required for SHEP cell spreading 
but not for their attachment on immobilized GDNF. These re-
sults are compatible with the HB-GAM–induced syndecan-3 
signaling that requires HS chains and regulates the cytoskeleton 
through the cortactin–SFK pathway (Rauvala et al., 2000).
Immobilized GDNF induces neurite 
outgrowth using HSPG
Cell spreading is a crucial step in many biological processes, 
including cell migration and neurite outgrowth. Soluble GFLs 
induce neurite outgrowth in a variety of neurons in vitro. To find 
out whether syndecan-3 interaction with immobilized GDNF is 
plasma membrane. HB-GAM was used as a marker for the 
brain ECM.
To test the biological effects of immobilized GFLs, we 
took advantage of the human neuroblastoma cell line SHEP, 
which lacks RET (as determined by PCR with specific human 
RET primers) but expresses the GDNF coreceptor GFR-1   
(Poteryaev et al., 1999). SHEP cells also express syndecan-3 
(Fig. 3 A). Immobilized on plastic microplates, GDNF, NRTN, 
and ARTN, but not PSPN, induced adherence and spreading of 
SHEP cells (Fig. 3, B and C). Spreading on immobilized GFLs 
involved 60–80% of the cells (Fig. 3, B and C) and occurred 
within 10–20 min after settling (Video 1). The spreading was 
accompanied by actin rearrangement and stress fiber formation 
(unpublished data), suggesting GFL-induced signaling.
For successful spreading of SHEP cells on immobilized 
GFLs, HSPGs are required because heparinase III treatment   
almost completely abolished cell attachment and spreading   
(Fig. 3, B and C). Heparinase III had no effect on SHEP cell ad-
hesion and spreading on uncoated tissue culture plates (Fig. 3 C), 
indicating that the cellular machinery responsible for the ob-
served adhesion was not affected and that the enzyme specifi-
cally disrupts the HS–GFL interactions. In agreement, SHEP 
cells failed to adhere and spread on PSPN or BSA, which lack 
affinity for HS. Treatment of SHEP cells with PI-PLC, an en-
zyme that cleaves the GPI anchor (Fig. 3 D), did not affect their 
attachment  and  spreading  on  GFL-coated  surfaces  despite 
blocking soluble GDNF signaling via GFR-1 (not depicted). 
These results suggest a GFR-1–independent mechanism for 
immobilized GFL signaling.
To further evaluate the role of GFR-1 and RET in im-
mobilized GDNF-induced cell spreading, we preincubated the 
GDNF-coated plate and the SHEP cells with GDNF function-
blocking antibodies. These antibodies prevent GDNF binding to 
GFR-1–RET but do not affect GDNF interaction with HS of 
syndecan-3 as they block the central part of GDNF (Xu et al., 
1998), which is dispensable for interaction with HS. Neither 
this treatment nor NCAM function-blocking antibodies had any 
effect on attachment and spreading of SHEP cells induced by 
immobilized GDNF (Fig. 3 D). Adherence of SHEP cells to 
GDNF is also independent of another polysaccharide related to 
HS. Chondroitin sulfate proteoglycans are not involved in the 
adhesion because it was not affected by removal of chondroitin 
sulfate chains from the cell surface by chondroitin sulfate lyase 
ABC (Fig. 3 D). Because SHEP cells do not express RET, we 
conclude that their attachment and spreading on immobilized 
GDNF, ARTN, or NRTN is a RET-independent process.
syndecan-3 in the rat glioma C6 cell line. Chemical cross-linking of 
125I-GDNF to C6 cells was followed by immunoprecipitation (IP) with antisyndecan-3 
antibodies in untreated cells (UNTR), cells pretreated with heparinase III (H’ase III), and cells pretreated with phosphatidylinositol-specific PLC (PI-PLC). Alter-
natively, a 150-fold molar excess of unlabeled (cold) GDNF and HB-GAM or 1 µg/ml heparin was added simultaneously with 
125I-GDNF. In the negative 
control, no syndecan-3 antibodies were added (No AB). The high molecular mass band in the top of the gel corresponds to the GDNF–syndecan-3 complex. 
Equal loading of the proteins was confirmed by silver staining of the gel (not depicted). (C) Western blotting (WB) of proteins extracted from dissociated 
P9 mouse brain and kidney tissues. Lysates from ECM and membrane-associated fractions were separated by SDS-PAGE, and Western blots were probed 
with anti-GDNF (top) or anti–HB-GAM antibodies (bottom). The bands corresponding to GDNF and HB-GAM are marked with asterisks. Molecular mass 
markers are shown on the right. (D) GDNF-induced syndecan-3 oligomerization visualized by FRET. FRET channel images of human embryonic kidney cells 
transiently transfected with syndecan-3 fusion constructs with YFP or CFP and stimulated with 100 ng/ml GDNF. Images were taken after GDNF stimulation 
at varying time points. FRET-corrected images were displayed in pseudocolors (red areas indicate high values of FRET, and blue areas indicate low values 
of FRET). Insets highlight a strong FRET signal at the plasma membrane, where syndecan-3 is targeted. Bar, 10 µM.
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Figure 3.  GDNF, NRTN, and ARTN induce SHEP cell adherence and SFK activation in an HSPG-dependent manner. (A) RT-PCR of the cDNA from SHEP 
cells with syndecan-3–specific primers. The resulting 140-bp band represents a syndecan-3 mRNA-derived PCR product (lane 2). (lane 1) Molecular weight 
markers with sizes in bp. (B) Crystal violet staining of SHEP cells plated on immobilized GDNF, ARTN, NRTN, and PSPN with or without heparinase III 
(H’aseIII) pretreatment. (C) Quantification of attached SHEP cells on immobilized GFLs. Some cells were treated with heparinase III. Quantification also 
includes controls with cell attachment on BSA and attachment of cells treated with heparinase III on tissue culture plates. (D) Quantification of SHEP cell 
adherence to immobilized GDNF and N-GDNF. Cells were plated on GDNF untreated, or they were pretreated with PI-PLC, chondroitinase ABC (Ch’ase 
ABC), NCAM function-blocking antibodies (NCAM BLK), or GDNF function-blocking antibodies (GDNF BLK). (C and D) Error bars show SEM from three 
independent assays. (E) Western blot (WB) for activated SFK in lysates from SHEP cells plated on GDNF, N-GDNF, or BSA. In control experiments, 
cells plated on GDNF were treated with heparinase III (HIII) or PI-PLC. Western blots were probed with anti-pY
418Src (top) or anti-Src (bottom) antibodies.   
(F) SHEP cell adherence and spreading on immobilized GDNF in the absence or presence of 2 µM SFK inhibitor SU6656. Cell spreading on immobilized 
GDNF was impaired in the presence of the inhibitor, whereas adherence of SHEP cells was not significantly affected by SU6656. (G) Adherence and 
spreading of SHEP cells infected with adenovirus expressing GFP (AdGFP) or dominant-negative Src (AdDN-Src/GFP) on immobilized GDNF. Transduction 
of cells with AdDN-Src/GFP resulted in SHEP’s failure to spread on immobilized GDNF. GFP-expressing adenovirus did not affect SHEP cell spreading on 
the GDNF matrix. Untreated, UNTR. Bars, 100 µM.159 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
showed that the process was neither affected by PI-PLC treat-
ment (Fig. 4 C) nor by NCAM function-blocking antibodies 
(not depicted), excluding the involvement of conventional re-
ceptors. The number of neurite-bearing neurons was signifi-
cantly lower after treatment of cells with heparinase III, and 
neurons failed to form processes on nonheparin-binding sub-
strates such as N-GDNF, PSPN, and BSA (Fig. 4, B and C),   
confirming the role of HS chains in the interaction. Likewise, 
important for these processes, we used rat embryonic (embryonic 
day 17 [E17]) hippocampal neurons, which express syndecan-3 
(Raulo et al., 1994; Lauri et al., 1999), GDNF, and very little RET 
(Trupp et al., 1997). When grown on HB-GAM substrate, these 
neurons extend numerous neurites with prominent syndecan-3 
localization in varicosities and growth cones (Raulo et al., 1994). 
Immobilized  GDNF  also  stimulated  neurite  outgrowth  in  E17   
hippocampal neurons (Fig. 4 A). Neurite outgrowth quantification 
Figure 4.  Immobilized GDNF induces neurite outgrowth in rat embryonic hippocampal neurons. (A) Neurite outgrowth in E17 rat hippocampal neurons 
on immobilized GDNF. Neurons are stained with tubulin-III antibodies. Bar, 20 µM. (B) Neurite outgrowth in hippocampal neurons plated on BSA. Neu-
rons are stained with tubulin-III antibodies. (C) Quantification of neurite outgrowth on immobilized GDNF, N-GDNF, PSPN, and BSA. Neurons plated 
on GDNF were untreated (UNTR) or preincubated with heparinase III (H’aseIII), PI-PLC, or 2 µM SFK inhibitor SU6656. As a control, soluble GDNF was 
added to neurons grown on BSA. Error bars show SEM from three to five independent experiments (*, P < 0.05). (D) Quantification of neurite outgrowth 
on immobilized GDNF and BSA from wild-type (syndecan-3
+/+) and syndecan-3–deficient (syndecan-3
/) neurons. Error bars show SEM from three inde-
pendent experiments (*, P < 0.05 by paired t test).JCB • VOLUME 192 • NUMBER 1 • 2011   160
Figure 5.  GDNF stimulates migration of embryonic mouse cortical neurons via syndecan-3. (A) E15 cortical neurons in a modified Boyden chamber 
migrate toward wtGDNF (squares) but not toward N-GDNF (triangles). Cortical neurons from syndecan-3–deficient mice (circles) migrate toward GDNF 
less efficiently than wild-type neurons. Error bars show SEM from three independent experiments. (B) Adult syndecan-3–deficient mice have less GABAergic 
neurons in the cerebral cortex. GABAergic cell density is significantly smaller in the most dorsal parts of the cortex (dmc) in syndecan-3 knockout brains 
(gray bar) compared with wild type (black bar). The cell density is almost identical to the wild type in the most lateral parts of the cortex (dlc and lc). dmc, 
dorsomedial cortex; dlc, dorsolateral cortex; and lc, lateral cortex. Error bars show SEM. (A and B) *, P < 0.05. (C) A schematic presentation shows 161 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
and Fig. S4). Neurons from syndecan-3 knockout animals failed 
to migrate toward GDNF but efficiently migrated toward brain-
derived neurotrophic factor (BDNF) beads (Fig. 5, D and E; and 
Fig. S4). These facts suggest that the promotion of GABAergic 
cell migration is mediated by GDNF–syndecan-3 interaction 
and that this effect is specific.
Furthermore, we found that at E15, the number of calbin-
din-positive  cells  was  significantly  increased  in  the  inter-
mediate zone (IZ) of the GEs of syndecan-3–deficient embryos 
compared with the wild types (Fig. 6, A, D, and G). The inten-
sity of the general neuronal marker Tuj1 was not altered in 
syndecan-3
/ sections (Fig. 6, B, E, and H). We therefore rea-
soned that the accumulation of GABAergic precursors in GEs 
may be caused by migration defects in mutant embryos. Be-
cause, after proliferation, the immature interneurons migrate 
tangentially from the GE to colonize the cortical plate, we   
assumed that the accumulation of GABAergic cells in the IZ 
during embryogenesis would result in interneuron deficiency 
in the adult cortex.
Consistently, the density of GABA-immunopositive cells 
was significantly lower in layers II–IV of the dorsomedial cor-
tex of adult syndecan-3–deficient mice (Fig. 5, B and C). The 
dorsomedial cortex is the most distant area along the tangential 
migration route from the place of interneuron origin. We found 
no difference in the width of the cortical layers (not depicted), 
and cortical areas proximal to the source of interneurons did not 
show any clear difference in the density of GABAergic neurons 
(Fig. 5, B and C).
Importantly, no signs of increased apoptosis were found 
in the syndecan-3–deficient brains (Hienola et al., 2006). Thus, 
the data indicate that the GDNF–syndecan-3 interaction plays a 
distinctive role in cerebral cortex development by promoting 
migration of GABAergic neurons.
Discussion
Brain development is remarkably dependent on HSPGs. Neural-
specific conditional knockout of EXT1, the enzyme that cata-
lyzes HS polymerization, showed that this protein is vital for 
brain patterning and axon scaffold formation in the forebrain 
(Inatani et al., 2003). HSPGs support activity of various growth 
factors, receptors, and guidance molecules during development, 
including FGFs or Robo-Slit signaling (Van Vactor et al., 2006). 
Here,  we  present  evidence  that  also  some  GFLs  could  use 
HSPGs as their signaling partners. In particular, GDNF, which 
has been recently implicated in embryonic cortical develop-
ment (Pozas and Ibáñez, 2005), could signal via brain HSPG 
the SFK inhibitor SU6656 prevented neurite outgrowth (Fig. 4 C). 
Soluble GDNF added to neurons grown on the BSA matrix failed 
to induce neurites. Because both N-GDNF and wild-type GDNF 
(wtGDNF) are basic proteins, we suggest that the observed dif-
ference in neurite outgrowth is not attributed to their electro-
static properties and is specific for the heparin-binding tail of 
GDNF. We conclude that the interaction between HSPGs and 
immobilized GDNF is involved in the induction of neurite for-
mation by GDNF in rat embryonic hippocampal neurons and 
that SFK activation is crucial for this process.
Because syndecan-3 is the only HSPG known to transmit 
extracellular signals via SFKs (Rauvala et al., 2000), we exam-
ined the involvement of syndecan-3 in GDNF-induced neurite 
outgrowth by performing the assay with E16 murine hippo-
campal  neurons  from  wild-type  and  syndecan-3  knockout   
animals (Reizes et al., 2001). At least 70% of neurons from 
wild-type mice developed long neurites when grown on im-
mobilized GDNF, whereas the number of neurite-bearing cells 
was significantly reduced in the culture of syndecan-3–deficient 
neurons (Fig. 4 D).
GDNF interaction with syndecan-3 drives 
migration of embryonic cortical neurons
Tangential migration and differentiation of cortical GABAergic 
neurons during embryonic development depends on GDNF, al-
though cortical neurons lack RET and NCAM (Fig. S3; Pozas 
and Ibáñez, 2005). In the transfilter cell migration assay, GDNF 
stimulated  substantial  migration  of  embryonic  cortical  cells 
compared with the tissue culture–treated adhesive surface or the 
polycationic filter surface (Fig. 5 A). In contrast, N-GDNF did 
not induce migration in this assay. Likewise, GDNF-stimulated 
migration of syndecan-3–deficient (Reizes et al., 2001) embry-
onic cortical neurons was strongly impaired (Fig. 5 A). Interest-
ingly, the highest concentration of GDNF could also stimulate 
migration of the knockout neurons, indicating the potential   
involvement of other GDNF receptors, e.g., GFR-1, as was 
previously suggested (Pozas and Ibáñez, 2005).
To establish in vivo relevance of GDNF interaction with 
syndecan-3, we performed a redirected GABAergic neuron mi-
gration assay in live brain explants. Agarose beads were soaked 
in various proteins and placed on top of E12.5 brain explants 
containing part of the medial ganglionic eminence (GE [MGE]) 
and developing cortex (Fig. 5 D, drawing; and Fig. S4). After   
56 h of incubation, the explants were fixed, and GABAergic 
neurons were identified by anticalbindin staining. We found that 
GABAergic neurons were attracted by GDNF beads but not by 
beads containing BSA, N-GDNF, or laminin (Fig. 5, D and E; 
the cortical areas where the density measurements were made. Arrows show the tangential migration route in E15 mice. The dotted line separates the 
schemes of an adult and E15 brain. lge, lateral ganglionic eminence; mge, medial ganglionic eminence; ve, ventricle; and hi, hippocampus. (D) Assay 
for redirected migration assay of GABAergic neurons. (top) GDNF attracts embryonic (E12.5) calbindin-positive neurons in living brain explants from 
wild-type (syndecan-3
+/+) mice but not from syndecan-3 knockout explants (syndecan-3
/). BSA fails to attract neurons. Bar, 200 µM. (bottom) The scheme 
of neuronal migration in the mouse brain of E12.5 (modified from Marín and Rubenstein, 2003). The explants were prepared from the area marked by 
the gray oval. Agarose beads soaked in various proteins were placed on top of the ventricular zone to stimulate neuronal migration. (E) Quantification of 
the migration assay. GDNF attracts GABAergic neurons from wild-type living explants (syndecan-3
+/+) but fails to do so in syndecan-3–deficient explants 
(syndecan-3
/). Neither N-GDNF nor BSA attracted neurons. For the evaluation of GABAergic neurons in syndecan-3
/ animals, six mice (12 brain 
slices) were processed. For the measurements in syndecan-3
+/+ animals, the brains from six mice (18 brain slices) were processed. Error bars show SEM 
(*, P < 0.01).
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partner in the developing brain. This is supported by the known 
expression patterns of syndecan-3, GDNF, and NRTN during 
brain development. Syndecan-3 associates with growing axons 
and neural processes and is found in most of the major neuronal 
migration routes (Nolo et al., 1995; Kinnunen et al., 1999). 
GDNF and NRTN are found in the cortex, striatum, and olfac-
tory bulb. In these areas, they are expressed by the glial guid-
ance structures, such as radial glia, and, thus, may provide cues 
syndecan-3 in cortical neurons, which lack the canonical GFL 
receptors RET and NCAM (Pozas and Ibáñez, 2005).
We find that GDNF, ARTN, and NRTN bind heparin with 
Kds in the range of 10–50 nM, which is comparable with other 
high  affinity  heparin-binding  molecules,  such  as  FGFs  or   
HB-GAM. More significantly, heparin-binding GFLs also bind 
the HSPG syndecan-3 isolated from the brain with similar affin-
ity, suggesting that syndecan-3 could be their natural binding 
Figure 6.  Syndecan-3 is required for the migration of immature interneurons in the developing telencephalon. (A–F) Coronal sections through the develop-
ing telencephalon of wild-type (syndecan-3
+/+, A–C) and syndecan-3
/ embryos (D–F) showing calbindin and Tuj1 immunostaining. (C and F) Merged 
images of calbindin and Tuj1 stainings. (G) The graph depicts the mean number of calbindin-positive cells in the medial (mcp) and lateral (lcp) cortical 
plate (cp) and in the intermediate zone (iz) of the GE. (H) The intensity of Tuj1 staining is not altered in syndecan-3–deficient brains. (G and H) Error bars 
show SEM of three embryos (syndecan-3
+/+, n = 3; and syndecan-3
/, n = 3). *, P < 0.01. Bar, 80 µm.163 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
Interestingly, because syndecan-3 has several HS chains, 
one molecule of syndecan-3 can simultaneously bind multiple 
GFL homodimers. Thus, compared with the GFR-–RET re-
ceptor complex, which binds one GFL dimer with very high   
affinity (0.01–0.5 nM; Cik et al., 2000; Leppänen et al., 2004), 
syndecan-3 is a high affinity/high capacity receptor for GFLs.
For secreted molecules, their ability to bind heparin is   
often associated with localization in the ECM. Our current work 
also supports the notion that GDNF is localized predominantly 
in the ECM and on the cell membrane (Fig. 2 C). Interaction 
with matrix HSPGs could dramatically change the properties 
and distribution of the heparin-binding GFLs. By analogy with 
other heparin-binding proteins, ECM could be the local high 
capacity store for GFL, participate in generation of GFL gradi-
ents, thus determining their precise spatiotemporal positioning, 
protect  GFLs  from  proteolysis  (Hynes,  1999;  Geiger  et  al., 
2001), or concentrate and present GFLs to their conventional 
GFR-–RET receptors (Sariola and Saarma, 2003).
It has been shown previously that coinfusion of heparin with 
GDNF, NRTN, or ARTN into rat striatum markedly increased 
their biodistribution (Hamilton et al., 2001), potentially leading to 
greater therapeutic effects of GFLs. Our findings indicate that this 
was because heparin prevented GFL binding locally to syndecan-3 
or other HSPGs in the brain ECM. This knowledge may allow a 
breakthrough in the successful therapeutic use of GFLs by pro-
moting the generation of variants lacking affinity to HSPGs and, 
thus, with increased biodistribution and bioavailability.
In our assays, immobilized, but not soluble, GDNF in-
duced spreading and robust (within the first hours of experimen-
tation) neurite outgrowth in embryonic hippocampal neurons 
(Fig.  4).  Syndecan-3  was  required  for  efficient  neurite  out-
growth (Fig. 4 D), and because SU6656 caused a drastic reduc-
tion in the number of neurites (Fig. 4 C), we assumed that SFK 
signaling was also involved in GDNF-induced neuritogenesis. 
We were unable to observe Src kinase activation in hippocam-
pal neurons by Western blotting as we did in the SHEP cells 
(Fig. 3 E). However, we found that, in PC6-3 pheochromo-
cytoma cells, 30-min pretreatment with 2 µM SU6656 efficiently 
blocked both neurite outgrowth and Src activation (unpublished 
data). Embryonic hippocampal neurons express negligible levels 
of RET, and neither release of GPI-anchored GFR-1 by PI-PLC 
nor NCAM-blocking antibodies had any effect on the GDNF-
induced neurite outgrowth. In contrast to our data, Paratcha   
et al. (2003) found that NCAM-blocking antibodies reduced 
GDNF-induced  neurite  outgrowth  in  hippocampal  neurons. 
This discrepancy could be a result of Paratcha and co-authors 
measuring the length of neurites initiated by GDNF, whereas 
we analyzed the number of neurons bearing neurites. Therefore, 
we studied the initiation of neurite outgrowth rather than the 
progression of already formed neurites. We have also observed 
that, in syndecan-3
/ neurons, immobilized GDNF had resid-
ual  activity  in  promoting  the  neurite  outgrowth  (Fig.  4  D).   
We have speculated that this effect may be caused by GFR-1, 
which was shown to be a ligand-induced cell adhesion molecule 
(Ledda et al., 2007)
The possible involvement of syndecan-3 in GDNF signal-
ing, supported by our in vitro data, could be highly relevant 
for migrating cells and growing axons (Golden et al., 1999; 
Ikeda et al., 1999; Koo and Choi, 2001). Our present findings 
indicate that the GDNF–HSPG interaction can stimulate neurite 
outgrowth and migration of primary neurons in vitro and impli-
cate syndecan-3 as the GDNF signaling partner in the brain.
Our results also show that PSPN may lack the ability to 
bind HSPGs in the ECM, raising an intriguing possibility that, 
unlike other GFLs, PSPN could diffuse longer distances in tis-
sues reaching body fluids. Therefore, PSPN may act as a circu-
lating hormone-type growth factor, offering an explanation for 
why PSPN and its specific coreceptor GFR-4 are expressed in 
different tissues (Lindahl et al., 2000).
Although syndecan-3 is the likely binding partner for im-
mobilized GFLs in the nervous system, different members of the 
syndecan family could be signaling receptors and/or coreceptors 
for GFLs in other tissues. For example, syndecan-1 could be the 
GDNF coreceptor in the developing kidney. Notably, targeted   
disruption of 2-O-sulfotransferase or glucuronyl C5-epimerase 
genes, which encode enzymes important for HS chain maturation, 
lead to renal agenesis in mice (Bullock et al., 1998; Li et al., 2003). 
This phenotype is markedly similar to GDNF-deficient mice that 
also lack kidneys (Moore et al., 1996; Pichel et al., 1996).
Syndecans, in general, can act as coreceptors for various 
growth factors or ECM molecules. Although they lack intrinsic 
kinase or phosphatase activity, their cytoplasmic domains can 
associate with cytoskeletal proteins or protein kinases, making 
it possible to transmit extracellular signals to the cytoskeleton 
via  SFK–cortactin,  ezrin–cdc42,  and  calcium/calmodulin- 
dependent serine protein kinase–protein 4.1 pathways (Rauvala 
et al., 2000; Yoneda and Couchman, 2003). Syndecan-3 is unique, 
as it is the only syndecan shown to signal independently of other 
receptors by activating SFKs (Raulo et al., 1994; Kinnunen   
et al., 1998). Our data indicate that immobilized GDNF, NRTN, 
and ARTN can also stimulate cell adhesion and spreading via 
syndecan-3 without involvement of their conventional receptors. 
We show that GDNF triggers SFK signaling in an HSPG- 
dependent manner and that the SFK activity is required for cell 
spreading but not for initial attachment. Based on these find-
ings, we speculate that the interaction between immobilized 
GFLs and syndecans first leads to the receptor anchoring to the 
GFL  matrix  and  then  subsequent  signaling  activates  SFKs, 
leading to full spreading. The intermediate step could involve 
syndecan oligomerization triggered by GFL binding. GDNF, 
NRTN, and ARTN all have at least one putative heparin binding 
site. In particular, the primary HS/heparin binding site is at the 
N terminus of GDNF (Fig. S2), which is highly flexible and 
unique to GDNF and is absent in other GFLs. The N terminus 
of GDNF is available for interaction with HSs both as a free and 
immobilized protein (Table S1). In NRTN and ARTN, the HS 
binding sites are likely to be located in the central region.   
Because  all  GFLs  are  produced  as  covalently  linked  homo-
dimers, they contain two heparin binding sites capable of link-
ing neighboring syndecan molecules. Indeed, the high molecular 
weight band detected after chemical cross-linking in C6 glioma 
cells  could  correspond  to  syndecan-3  oligomers  in  complex 
with GDNF (Fig. 2 B). Syndecan-3 oligomerization was also 
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assay (Fig. S4). These facts further support the specific role of 
syndecan-3 in the GDNF signaling pathway.
After leaving GE, the immature interneurons migrate tan-
gentially to colonize the cortical plate. We detected the accumu-
lation of the GABAergic cells in the IZ of the GE of syndecan-3 
knockout mice, suggesting the migratory defect in these cells 
(Fig. 6). Other cells (Tuj1 stained) did not accumulate in the IZ, 
suggesting that, in the tangential migratory stream, the effect is 
confined to the interneurons. It is unclear what restricts the   
effects of GDNF to the population of GABAergic cells. We sug-
gest that GFR-1 expression is important for GDNF to exert its 
effects in vivo (Pozas and Ibáñez, 2005).
Consistently, we can detect a clear drop in the density   
of GABAergic cells in the dorsal cerebral cortex of the adult 
syndecan-3–deficient mice (Fig. 5 B), and as neural proliferation 
and differentiation are normal in syndecan-3 knockout mice 
(Hienola et al., 2006), we conclude that, in the absence of   
syndecan-3, migration of GABAergic neurons is defective. The 
brain phenotype of syndecan-3–deficient mice is markedly sim-
ilar to the GDNF knockout phenotype found by Pozas and 
Ibáñez (2005), suggesting a likely physiological interaction   
between these molecules.
In summary, this work identifies syndecan-3 as a novel re-
ceptor for immobilized GDNF, NRTN, and ARTN, which is 
fundamentally different from that for diffusible GFLs. GFL   
interaction with syndecan-3 (or a receptor complex consisting of 
syndecan-3 and an unknown signal-transducing molecule) and 
with GFR-–RET or GFR-–NCAM induces distinct biological 
during cortical development. During cerebral cortex formation, 
inhibitory GABAergic interneurons originate mainly from the 
MGE and then migrate tangentially into the developing cortical 
layers (Fig. 5 C; Marín and Rubenstein, 2003). Recently, mouse 
cortical GABAergic neurons were shown to migrate along the 
GDNF gradient from the MGE toward the cortex. These neu-
rons lack RET and NCAM, and so it has been suggested that an 
alternative GDNF receptor system drives their migration (Pozas 
and Ibáñez, 2005). Detailed analysis by Pozas and Ibáñez (2005) 
demonstrated that GDNF and GFR-1 knockout animals have 
significantly fewer GABAergic neurons in their cortex, whereas 
mice lacking RET and NCAM have the normal number of   
GABAergic cortical neurons, indicating that GDNF acts as a 
chemoattractant for GABAergic cortical neurons via a novel 
RET- and NCAM-independent pathway.
Here, we demonstrate that syndecan-3 mediates GDNF-
induced migration and differentiation (Fig. S3) of cortical neu-
rons and, specifically, of the GABAergic population. We used   
a transfilter migration assay for embryonic cortical neurons, 
whereas a specific GABAergic neuronal population was studied 
by quantifying their redirected migration in living explants.   
In both assays, migration was specifically stimulated by GDNF 
but not by N-GDNF, which cannot bind syndecan-3 (Fig. 5, A, 
D, and E). Syndecan-3–deficient neurons failed to migrate to-
ward GDNF in both assays, but they were still capable of migra-
tion toward laminin in the transfilter assay (unpublished data). 
Knockout neurons also migrated toward neurotrophin BDNF, 
which signals via TrkB and p75 receptors, in the migration   
Figure 7.  Hypothetical model of GDNF sig-
naling mediated by syndecan-3. Matrix-bound 
GDNF may directly induce syndecan-3 signal-
ing via interaction with heparan sulfate (HS) 
chains of the receptor. Alternatively, syndecan-3 
can  modulate  RET  (or  NCAM)  signaling  in-
duced by soluble GDNF.165 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
dynamics as Kd = ka/kdis or from equilibrium response (R) using a simple 
Langmuir fit, R = (Rmax × C)/(Kd + C), in which C is the ligand concentra-
tion. Because all ligands except PSPN displayed background binding to a 
control BSA cuvette, Kds were also determined in a system in which GDNF, 
ARTN, NRTN, and PSPN were immobilized to the aminosilane surface and 
different concentrations of heparin were presented in a solution. The Kds 
were determined from binding dynamics and equilibrium response. The 
same cuvettes were used to test binding of HSPG syndecan-3, which was 
purified as an ectodomain from early postnatal rat brains by HB-GAM   
affinity chromatography (Raulo et al., 1994).
Specifically desulfated heparins (Takano et al., 1998) were used to 
assess the involvement of different sulfate groups in the GDNF–heparin   
interaction by following direct binding to the GDNF cuvette or by competing 
out GDNF binding to the heparin-BSA cuvette. Kds were determined from 
direct binding using increasing GDNF concentrations and by fitting the 
data to R = (Rmax × C)/(Kd + C) for heparin. For desulfated heparins, the best 
fit was achieved using the equation R = (Rmax1 × C)/(Kd1 + C) + (Rmax2 × C)/
(Kd2 + C), in which Kd1 and Kd2 are apparent Kds derived for two heparin 
sites of different affinities with maximum equilibrium response Rmax1 and 
Rmax2, respectively. The presence of a higher affinity component (Kd1 of   
30–40 nM) for all desulfated heparins could be a result of incomplete de-
sulfation and/or the presence of residual sites with high affinity for GDNF.
Chemical cross-linking and immunoprecipitation
Glioma C6 cells were plated on 6-well plates and grown to 70% confluence. 
Cells were incubated with 1 nM 
125I-GDNF for 2 h in binding buffer (DME, 
0.2% BSA, and 15 mM Hepes, pH 7.2) on ice. The unbound ligand was re-
moved by washing three times with ice-cold PBS. The chemical cross-linker 
ethyl-dimethyl-aminopropyl-carbodimide  supplemented  with  N-hydroxy-
succinimide was incubated with cells for 20 min at room temperature in PBS. 
The reaction was quenched with TBS for 15 min, and cells were lysed in the 
lysis buffer (TBS, 1% Triton X-100, 1% NP-40, 2 mM EDTA, 1 mM PMSF, and 
protease inhibitor mixture [Complete; Roche]). Cell lysates were immunopre-
cipitated with antisyndecan-3 antibodies (Nolo et al., 1995) and resolved 
on 7.5% SDS-PAGE. Autoradiography was performed with an image ana-
lyzer (BAS1500; Fujifilm). For heparinase III or PI-PLC treatment, cells were 
incubated with 10 mU/ml heparinase III or with 1 U/ml PI-PLC, respectively, 
for 1 h at 37°C and 5% CO2 before 
125I-GDNF addition.
RT-PCR
RNA from SHEP cells was isolated using RNAwiz (Applied Biosystems). First 
strands were built with random primers using Superscript II (Invitrogen).   
35 cycles of PCR were performed with 5-ATGGCCATTGCTTACCTGG-3 
as a forward primer for syndecan-3 and 5-AAGCGCATGGCTGTCTCAA-3 
as a reverse primer. DyNAzyme II (Finnzymes) polymerase was used, and 
the annealing temperature was 58°C.
Separation of membrane-bound and ECM-bound  
protein fractions of mouse organs
Postnatal day (P) 9 mouse brains and kidneys were dissociated in 1.5 ml 
of 10-mM Tris-HCl, pH 7.5 (containing protease inhibitor mix, 1 mM EDTA, 
and 1 mM PMSF), by passing them through a 20-gauge needle on ice.   
After  10-min  incubation  on  ice,  insoluble  material  was  spun  down  at 
13,000 rpm in a tabletop centrifuge for 60 min at 4°C. The supernatant 
was collected and labeled as the ECM fraction. The pellet was dissolved in 
PBS with 1% NP-40 for 30–60 min on ice and centrifuged at 13,000 rpm 
for 90 min at 4°C. The supernatant was collected and labeled as the mem-
brane fraction. Volumes in both the ECM and membrane fractions were 
equalized. Fractions were separated on 15% SDS-PAGE, and Western 
blots were stained either with GDNF antibodies (Santa Cruz Biotechnol-
ogy, Inc.) or with HB-GAM antibodies (Rauvala, 1989). Anti–rabbit horse-
radish peroxidase–conjugated secondary antibodies (GE Healthcare) 
were used for the primary antibody detection. For imaging chemilumines-
cence, the LAS-3000 imaging system (Fujifilm) was used.
FRET experiments
To study GDNF-induced syndecan oligomerization, we tagged rat syndecan-3 
with YFP and CFP. The sequences were placed immediately after the trans-
membrane domain of the receptor in the cytosolic part after Tyr409 residue.
The constructs were transfected into HEK293T cells seeded on   
20 µg/ml poly-l-lysine–coated 35-mm glass-bottom culture dishes (MatTek) 
with FuGene 6 (Roche). Cells were incubated for a few hours in serum-free 
medium before FRET measurements at 37°C and 5% CO2. During the stim-
ulation with 100 ng/ml GDNF for up to 40 min and during image acquisi-
tion, the temperature was decreased to 22–24°C.
effects (Fig. 7). Our results clearly show that, in the absence of 
conventional receptors, HSPG syndecan-3 is required for im-
mobilized GDNF-induced intracellular signaling leading to the 
activation of SFKs, triggering cell spreading, neurite outgrowth, 
and neuronal migration. Moreover, GDNF interaction with syn-
decan-3 is likely to be important for brain cortex development.
Our simplified model (Fig. 7) illustrates the idea that the 
interaction of GDNF, NRTN, and ARTN with the HS of syndecan-3 
can concentrate and present GFLs to their conventional recep-
tors GFR-–RET or GFR-1–NCAM. The model predicts a 
new regulatory step in GFL signaling: cleavage of HS or the 
syndecan-3 ectodomain to regulate the release of diffusible 
GFLs required for GFR-–RET receptor activation. We propose 
that the long-range (chemotactic) signals exerted by diffusible 
GFLs are mediated by GFR-–RET, whereas the short-range 
effects are transduced via syndecan-3. Our study indicates, for 
the first time, that a growth factor may activate signal transduc-
tion  through  HSPG  and  that  the  same  signaling  molecule, 
GDNF, elicits different biological effects via different receptors 
when immobilized or as a free diffusible protein (Fig. 7).
Materials and methods
Cell cultures and reagents
The rat glioma C6 cell line and the mouse neuroblastoma cell line Neuro2a 
were obtained from American Type Culture Collection. Early passage RET-
deficient human SHEP cells were provided by M. Billaud (Centre National 
de  la  Recherche  Scientifique,  Lyon,  France).  MG87-RET  cells  were  ob-
tained  from  C.F.  Ibáñez  (Karolinska  Institute,  Stockholm,  Sweden).  Rat   
hippocampal neurons were isolated from E17 embryos. Mouse cortical 
neurons were isolated from E15 embryos. The use of experimental animals 
was approved by the Committee for Animal Experiments of the University 
of Helsinki and the chief veterinarian of the County Administrative Board 
(permissions  HY  173–04  and  55–06  and  ESLH-2006-04080/Ym-23). 
Low molecular weight heparin, heparin-BSA, ethyl-dimethyl-aminopropyl-
carbodimide/N-hydroxysuccinimide cross-linker, lactoperoxidase, PI-PLC, 
chondroitinase ABC, globulin-free BSA, and cell culture–tested BSA were 
purchased from Sigma-Aldrich. SU6656 was bought from EMD. Hepari-
nase III was obtained from Seikagaku Corp. (Seikagaku’s trademark for 
this product is Heparitinase I). The dominant-negative Src adenoviral con-
struct was a gift from D. Kaplan (Hospital for Sick Children, Toronto, Can-
ada). Desulfated heparins were provided by R. Takano (Okinawa National 
College of Technology, Okinawa, Japan). G90 antibodies were provided 
by R. Marino (Amgen, Inc., Thousand Oaks, CA). Tritium-labled heparin 
was a gift from U. Lindahl (University of Uppsala, Uppsala, Sweden).
GFL iodination and binding to heparin-Sepharose
GDNF, ARTN, NRTN, and PSPN were purchased from PeproTech or R&D 
Systems. GFLs were enzymatically labeled with carrier-free [
125I]NaI (GE 
Healthcare)  by  the  lactoperoxidase  method  to  a  specific  activity  of 
100,000–200,000 cpm/ng as described previously (Lindahl et al., 2001). 
15,000–20,000 cpm of iodinated GFLs together with 10 µg of the same 
unlabeled protein as a carrier were injected into a 1-ml heparin–Sepharose 
column (GE Healthcare) in phosphate buffer, pH 7.2, containing 100 mM 
NaCl and 10 mg/ml BSA. After washing with five volumes of the same 
buffer, 2 ml of step-wise elution was performed with increasing NaCl con-
centration. The resulting fractions were counted on a scintillation counter 
(Rackbeta 1214; LKB/Wallac).
SPR studies
The affinities of GFLs for heparin and heparin-like molecules were deter-
mined by SPR using the IAsys system (Thermo Fisher Scientific). Planar 
aminosilane cuvettes (Thermo Fisher Scientific) were used to avoid prob-
lems with mass transport, which occur frequently with matrix surfaces. In 
the initial approach, heparin-BSA was immobilized to the cuvette surface 
according to the manufacturer’s instructions, and different ligand concen-
trations were used to determine association (ka) and dissociation (kdis) rates 
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(PeproTech) or N-GDNF for 10 min at 37°C. Next, cells were lysed on 
ice,  and  the  lysates  were  immunoprecipitated  with  anti-RET  antibodies   
(C-20; Santa Cruz Biotechnology, Inc.). The precipitates were SDS-PAGE 
resolved, transferred to nitrocellulose membranes, and probed with phos-
photyrosine antibodies (4G10; Millipore). To ensure that equal amounts of 
RET were precipitated in each sample, the filters were stripped and re-
probed with antibodies to RET.
Neurite  formation  in  cultured  dorsal  root  ganglion  neurons  was 
tested in the presence of N-GDNF or wtGDNF as described previously 
(Paveliev et al., 2004). In brief, dorsal root ganglia were dissected from 
thoracic and lumbar spinal segments of 1-mo-old mice (Naval Medical Re-
search Institute). Ganglia were cleaned from nerves and incubated for   
20 min in PBS containing 0.15% collagenase I, 0.025% trypsin, and 0.4% 
BSA at 37°C followed by trituration in HBSS. Cells were plated (culture 
density of 500–1,000 neurons/cm
2) on glass coverslips. Coverslips were 
precoated with 1 mg/ml polyornithine overnight at 4°C and then with   
100 ng/cm
2 laminin for 4 h at 37°C. Culture medium included 50% F12 and 
50% DME supplemented with glutamine, penicillin, streptomycin, and serum 
substitute containing 0.35% BSA, 60 ng/ml progesterone, 16 μg/ml   
putrescine, 400 ng/ml l-thyroxine, 38 ng/ml sodium selenite, and 340 ng/ml 
triiodothyronine. N-GDNF was applied at the time of plating neurons, 
and cultures were maintained for 12 h after plating. After that, neurons 
were fixed with 4% PFA in PBS and stained for PGP9.5. The immuno-
stained cultures were viewed using the 20× objective of a fluorescent micro-
scope (Axioplan 2; Carl Zeiss, Inc.).
Neurite outgrowth assay in hippocampal neurons
Hippocampi were dissected from E17 embryonic rat brains under the   
microscope, transferred to the preparation media (HBSS without Ca
2+ and 
Mg
2+ supplemented with 1 mM sodium pyruvate [Invitrogen] and buffered 
by 10 mM Hepes, pH 7.2), and then partially digested by papain and tritu-
rated in the preparation media supplemented with DNase I. Cells were 
washed  with  HBSS  containing  Ca
2+  and  Mg
2+  and  transferred  to  the 
growth media (neurobasal media with B27 supplement, 2 mM l-glutamine, 
25 µM glutamic acid, penicillin, and streptomycin [Invitrogen]). For enzy-
matic treatments, neurons were kept in the growth media supplemented 
with 0.2% BSA at 37°C for 1 h. SU6656 (Millipore) was used at a 2-µM 
concentration. After the treatment, cells in the same media were seeded on 
the protein-coated coverslips (see Cell adhesion assay), and after 10 min, 
the media were changed for B27-free media. Neurons were incubated at 
37°C in 5% CO2 for 18 h.
For immunocytochemistry, neurons were washed with PBS and fixed 
with 4% PFA, permeabilized with 0.1% Triton X-100, and stained with rab-
bit polyclonal antiserum to protein gene product 9.5 (Affiniti), neuron-specific 
class  III  tubulin-III  clone  Tuj1  antibodies  (BABCO),  or  with  antibodies 
against the neurofilament triplet 13AA8 (Ylikoski et al., 1993). The second-
ary antibodies used were Alexa Fluor 488–conjugated goat anti–rabbit or 
anti–mouse (Invitrogen).
The immunostained cultures were viewed using the 20× objective of 
a fluorescent microscope (Axioplan 2). Neurons with the processes at least 
two times longer than cell body diameter were considered process bearing. 
Three coverslips were used in parallel, and 100 neurons per coverslip were 
counted. Results were derived from three to five independent experiments.
Hippocampi from mouse E16 embryonic brains were dissected in 
HBSS media and then partially digested with trypsin. After 15 min at 
37°C, trypsin was blocked with HBSS supplemented with 10% FBS and 
DNase I. Cells were washed by centrifugation and resuspended in glial 
cell–conditioned media (neurobasal media with B27 supplement and 0.5 mM 
l-glutamine, which was kept overnight on glial cells) to the final density of 
150,000 cells/ml. Neurons were seeded on the protein-coated coverslips 
(see Cell adhesion assay), and after 18-h incubation at 37°C, 5% CO2 
neurites were counted on living neurons using an inverted microscope (IMT-2; 
Olympus) with a 20× objective. Results were derived from three indepen-
dent experiments and expressed as means ± SEM.
Cortical neuron transfilter migration assay
Cortical lobes from E15 mouse brains were dissected under a stereomicro-
scope and dissociated using a 20-gauge needle and a syringe in DME 
containing 10% FCS. The cortical preparation was spun down at 1,000 rpm 
for 5 min, and the pellet was washed with culture medium containing   
serum. The pellet was carefully resuspended, and the preparation was   
allowed to sediment for 5 min more before the cleared supernatant was 
collected. The cells in the supernatant were allowed to recover in serum-
containing DME for 30–60 min. Recovered cells were washed once with 
the assay medium (DME with 10 mg/ml BSA, l-glutamine, and antibiotics) 
and resuspended in the same medium.
FRET measurements were performed as described previously (Hienola 
et al., 2006). In brief, FRET was quantified with three filter sets: CFP chan-
nel, excitation (EX) D436/20×, emission (EM) D480/40m, and dichroic 
longpass 455 (DCLP); FRET channel, EX D436/20×, EM D535/30m, and 
DCLP 455; and YFP channel, EX HQ500/20×, EM HQ535/30m, and 
DCLP 515 (Chroma Technology Corp.).
Images were recorded in live transfected cells using Cell^R Imaging 
Systems (Olympus) with a 60× objective. The background subtraction was 
made before FRET calculations.
All images were corrected for cross talk from CFP and YFP channels 
using the linear spectral unmixing formula Fc = FRET channel  a × CFP 
channel  b × YFP channel, in which a and b are correction factor values for 
CFP and YFP, which were found to be 0.4235 ± 0.018 (n = 25) and 0.0238 ± 
0.0007 (n = 21), respectively (described in the following paragraph).
CFP and YFP were expressed separately and for each fluorophore. 
The emission from the FRET channel was divided by the emission measured 
with either the CFP or YFP channels: a = FRET/CFP (0.4235 ± 0.018) and 
b = FRET/YFP (0.0238 ± 0.0007). In Fig. 2 D, FRET-corrected images 
were displayed in pseudocolors (red areas designate high values of FRET, 
and blue areas designate low values of FRET).
Cell adhesion assay
Cell adhesion assays were essentially performed as described previously 
(Weinacker et al., 1994). To prepare protein-coated surfaces, the protein of 
interest (10 µg/ml in PBS) was applied to 96-well ELISA plates (Greiner) or 
to glass coverslips for 12–18 h at 4°C. After incubation, the surfaces were 
washed with PBS and blocked with 1% globulin-free BSA for 2 h. Some 
GDNF-coated surfaces were incubated with 20 µg/ml G-90 GDNF func-
tion-blocking antibodies (Xu et al., 1998) for 2 h at room temperature.
Subconfluent SHEP cells were harvested in PBS supplemented with 
10 mM EDTA for 5 min at 37°C. Cells were washed with incubation buffer 
(RPMI  1640,  0.2%  BSA,  and  15  mM  Hepes,  pH  7.2),  and  10,000–
40,000 cells per well were plated on the protein-coated surface. Plates 
were centrifuged for 5 min at 10 g and incubated for 1 h at 37°C in 5% 
CO2. After incubation, cells were washed with PBS, fixed with methanol 
supplemented with crystal violet for 15 min at room temperature, and 
washed again with PBS. The remaining cells were stained and counted on 
an inverted microscope (DMIRB; Leica) with a 10× objective in five fields 
per well, and the resulting cell number was calculated for the whole well. 
Some cells were pretreated with heparinase III, 1 U/ml PI-PLC, and 0.3 U/ml 
chondroitinase ABC for 1 h at 37°C in 5% CO2 or with 20 µg/ml NCAM-
blocking antibodies (AB5032; Millipore) for 15–30 min on ice. Live SHEP 
cells spreading on immobilized GDNF were imaged for 20 min using an 
imaging system with a digital camera (Imago QE; TILL Photonics) equipped 
with heating (37°C) and CO2 supply (5%) chambers.
Src kinase phosphorylation assay
SHEP cells from 10-cm plates were harvested (see the previous paragraph) 
and plated on GDNF-coated 35-mm petri dishes. Some cells were pre-
treated with heparinase III and PI-PLC (see the previous paragraph). Cells 
were allowed to sediment for 10 min at room temperature and then were 
transferred to 37°C for an additional 15 min. Cells were lysed in the lysis 
buffer (TBS, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS, 10% 
glycerol, 1 mM Na3VO4, 1 mM PMSF, and protease inhibitor mixture).   
Lysates were analyzed on 10% SDS-PAGE, and Western blots were stained 
with anti-pY
418Src or anti-pp60Src antibodies (Invitrogen). Some cells were 
pretreated with heparinase III or PI-PLC.
Isolation and characterization of heparin binding–deficient GDNF mutant
The sequence encoding residues 39–134 of mature human GDNF and an 
N-terminal  FLAG  tag  was  subcloned  into  the  pFASTBAC1  (Invitrogen)-
based  baculovirus  transfer  vector  pK503.9  (Keinänen  et  al.,  1998;   
Leppänen et al., 2004). For the baculoviral infection, we used Sf9 insect 
cells grown in serum-free medium (SF900II; Invitrogen) supplemented with 
50 µg/ml gentamicin (Sigma-Aldrich) at 28°C. At 3 d after infection, the 
soluble secreted N-GDNF was produced at 0.5–1 mg/liter concentra-
tion. N-GDNF was purified from culture supernatants by anti-FLAG M1 
affinity  chromatography  (Sigma-Aldrich)  followed  by  cation  exchange 
chromatography on an S column (UNO; Bio-Rad Laboratories). The purity 
of the GDNF proteins was tested on 15% SDS-PAGE.
RET phosphorylation assay was performed as described previously 
(Leppänen et al., 2004). In brief, MG87-RET cells (Eketjäll et al., 1999) 
were transiently transfected with GFR-1. At 20 h after transfection, media 
were exchanged for a serum-free DME (Sigma-Aldrich), and cells were 
starved for 4 h. Then cells were stimulated with 100 ng/ml (3.3 nM) GDNF 167 Syndecan-3 is a novel receptor for GDNF • Bespalov et al.
Immunohistochemistry was performed as follows: after fixation, ex-
plants were washed in PBS, dehydrated through a graded series of metha-
nol in PBS, and incubated in Dent’s fixative (80% methanol and 20% 
DMSO) for 1 h. Explants were then washed in TBSTD (TBS, 0.1% Tween, 
and 5% DMSO) and blocked in TBSTD containing 5% BSA and 0.4% goat 
serum (TBSTDB) overnight at 4°C. Afterward, polyclonal rabbit anticalbin-
din antibodies (Swant) diluted 1:1,000 in TBSTDB were applied to the ex-
plants for 48 h at 4°C. After 2 d, explants were washed in TBSTD and 
incubated overnight with Alexa Fluor 488– or Alexa Fluor 568–conjugated 
anti–rabbit antibodies (Invitrogen) diluted 1:400 in TBSTDB. Unbound anti-
bodies were washed off with TBSTD, and explants were mounted in gelva-
tol. Images were acquired with a fluorescent microscope (AX70 Provis; 
Olympus) using a 4× objective lens, a charge-coupled device camera, and 
AnalySIS acquisition software.
Densitometry was performed as follows: optical densities of selected 
parts of the images were measured using Aida software (Raytest). To esti-
mate calbindin-positive neuron migration to the beads, we first calculated 
for each bead the difference between optical density in its close proximity 
and under the bead itself. This number was divided by the difference of 
optical densities of two circles of different diameters located approximately 
one bead diameter apart from the bead and normalized to their area ratio. 
Then, the obtained values for all beads were averaged within one explant. 
Results are presented as means ± SD of 7–11 independent explants from 
three to four litters. Statistics was performed with help of the demo version 
of Prism software (GraphPad Software, Inc.).
Estimation of GABAergic cell numbers in the mouse brain
The  measurement  of  GABAergic  precursor  number  migrating  from  the 
MGE  tangentially  was  performed  using  confocal  microscopy  on  slides 
stained with calbindin and Tuj1. The embryos were removed at E15 by 
caesarean section into the Dulbecco nutrient medium, pH 7.4, dissected 
out under a stereomicroscope, fixed in 4% PFA for 72 h at 4°C, cryopro-
tected in 30% sucrose, and cut into 50-µm-thick coronal slices with a cryo-
stat (CM3050; Leica). Six consecutive series of slices were collected in 
each well, and the distance between two slices was 300 µm. The slices 
were collected into 15% sucrose and rinsed in PBS, pH 7.4. Slices were 
dehydrated in a series of methanol (30, 50, and 80% in PBS), treated in 
Dent’s fixative, rinsed in TBSTD, pH 7.4, and then blocked in BSA-TBSTD 
(5% BSA and 0.4% sheep serum in TBSTD) for 3 h at room temperature. 
The samples were incubated in primary antibodies in BSA-TBSTD for 48 h 
at 4°C. The antibodies used were rabbit anticalbindin (1:400; Swant) and 
mouse  anti-Tuj1  (1:5,000;  BABCO).  After  washing  in  TBSTD,  samples 
were placed overnight at 4°C with the specific secondary antibodies   
(Alexa Fluor 568 goat anti–rabbit and Alexa Fluor 488 donkey anti–mouse, 
1:400;  Invitrogen).  The  samples  were  rinsed  in  TBSTD,  incubated  in 
Hoechst (1:1,000; Invitrogen), and mounted on Superfrost Plus slides with 
ProLong Gold antifade reagent (Invitrogen). Z-series image stacks were ac-
quired with a confocal microscope (TCS SP5; Leica) using an HCX Plan 
Apochromat 20× glycerol objective and analyzed with the software Imaris 
(Bitplane).  Calbindin-positive  cells  were  counted  with  the  experimenter 
blind to the genotype of the sample from the medial area of embryonic 
brain at the medial and the lateral part of the cortical plate and the IZ of 
the GEs. The intensity of Tuj1 epifluorescence was measured with Image-
Pro software (Media Cybernetics). The Student’s t tests were performed   
using Excel 2007 software (Microsoft).
To count GABAergic neurons in the adult cortex, 5-mm-thick coronal 
paraffin  sections  from  adult  syndecan-3  wild-type  and  knockout  brains 
were dewaxed and hydrated. 1 µg/ml antibodies against GABA (Milli-
pore) was diluted in PBS containing 2% BSA and 0.3% Triton X-100. The 
sections were incubated with the antibody solution overnight, and biotinyl-
ated secondary antibodies were used to detect the immunostaining signal. 
For quantifications, the required brain areas (dorsomedial, dorsolateral, 
and lateral cortices) were photographed at 63× magnification with a cam-
era (AxioCam; Carl Zeiss, Inc.) mounted in a microscope (AxioPlan; Carl 
Zeiss, Inc.). Cell density estimates from photographs were made by the   
selector method (Everall et al., 1997) using ImageJ software.
Online supplemental material
Fig. S1 shows GFL interaction with desulfated heparins. Fig. S2 shows the 
characterization of the N-GDNF variant and SHEP cell spreading. Fig. S3 
shows differentiation of GABAergic cells in the culture of E12.5 MGE cells 
on immobilized GDNF. Fig. S4 shows the migration assay of GABAergic neu-
rons. Video 1 shows live imaging of SHEP cells spreading on immobilized 
GDNF.  Table  S1  shows  the  analysis  of  GFL  binding  to  heparin  and   
syndecan-3. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201009136/DC1.
Transwell filters (Costar) with 12-µm pores or polycarbonate filters 
saturated  with  100  µg/ml  poly-l-lysine  were  coated  with  GDNF  or   
N-GDNF in 1-, 10-, and 100-µM concentrations overnight at 4°C and 
equilibrated with assay medium for 30 min in a 37°C incubator before 
use. The spontaneous and random migratory activity of cortical cells was 
controlled with uncoated filters.
Embryonic cortical cells were plated on the filters at 150,000 cells 
per filter and left to migrate for 16 h. Wild-type embryonic cortical cells 
were used to examine the migration-inducing potential of GDNF and   
N-GDNF. Embryonic cortical cells from syndecan-3 knockout mice were 
used to determine the amount of migration to GDNF in the absence of   
syndecan-3. The filters were fixed with methanol for 20 min, stained with 
1% toluidine blue for 20 min, and washed with PBS several times. After the 
last wash, the noncoated sides of the filters were scrubbed clean with cot-
ton sticks, and the filters were left to dry. The number of cells that had   
migrated to the coated surface of the filters was calculated using an inverted 
light microscope (IX71; Olympus). In this assay, syndecan-3–deficient neu-
rons and wild-type neurons migrated equally well to laminin, suggesting that 
the general migratory systems are intact in these knockout neurons.
Isolation of MGE cells to study GDNF-induced differentiation of 
GABAergic cells
MGEs were dissected from the brains of E12.5 embryos (plug day was 
counted as E0.5) in the HBSS buffer containing 1 mM sodium pyruvate and 
10 mM Hepes, pH 7.2. MGEs were treated with 1 mg/ml papain and   
10 µg/ml DNase I in HBSS containing 5 mg/ml glucose, 0.2 mg/ml BSA, 
and 0.5 mM EDTA at 37°C for 5–10 min. After incubation, tissues were   
allowed to precipitate, supernatant was replaced by trituration media (HBSS, 
1 mM sodium pyruvate, 10 mM Hepes, pH 7.2, and 10 µg/ml DNase I), 
and trituration was performed. Trituration was repeated three times, and 
cell-containing supernatants were combined. Cells were precipitated by 
centrifugation. Cells were washed twice with growth media (neurobasal 
media supplemented with 100 µg/ml primocin, 2 mM glutamine, and B27 
supplement),  counted,  and  plated  on  poly-l-ornithine  or  growth  factor–
coated coverslips (25,000 cells per coverslip). After 48 h, cell were fixed 
by 4% PFA and 0.25% glutaraldehyde in PBS for 15 min.
After 48 h in culture, cells were fixed by 4% PFA and 0.25% glutar-
aldehyde in PBS for 15 min, washed two times with PBS, and permeabi-
lized with PBS-T (PBS and 0.1% Triton X-100) for 15 min. Then cells were 
treated three times for 10 min with 1 mg/ml sodium borohydride solution 
and washed three times with PBS and three times with PBS-T solution.   
To block nonspecific binding, cells were incubated in 10% normal goat   
serum in PBS-T for 1 h and probed with anti-GABA antibodies (diluted 
1:1,000 in blocking solution) overnight at 4°C. To visualize GABA-positive 
cells,  anti–rabbit  antibodies  conjugated  with  Alexa  Fluor  488  (diluted 
1:400 in blocking solution) were used. Nuclei were stained with DAPI 
(Sigma-Aldrich). Unbound antibodies and DAPI were washed out with   
PBS-T,  and  coverslips  were  mounted  in  gelvatol.  Epifluorescent  images 
were collected with a microscope (BX61; Olympus) using AnalySIS acqui-
sition software (Soft Imaging System GmbH). The length of the neurites was 
measured with the help of ImageJ software (National Institutes of Health).
GABAergic neuron migration assay
The final protocol was developed on the basis of the following publications: 
Ledda et al. (2002), Nasrallah et al. (2006), Pozas and Ibáñez (2005), 
Sahlberg et al. (2002), and Shulga et al. (2008). Growth factor–soaked 
beads were prepared as follows: 5 µl agarose beads (Affi-Gel blue; Bio-
Rad Laboratories) were incubated in the PBS containing 0.1% BSA with 2 µg 
GDNF, N-GDNF, laminin, or BDNF in the final volume of 20 µl for 1 h at 
37°C. Immediately before use, beads were washed with PBS.
Brain explants were prepared as follows: brain explants containing 
part of the MGE and developing cortex were dissected from wild-type and 
syndecan-3 knockout E12.5 embryos in ice-cold Dulbecco’s PBS (Life Tech-
nologies) under a stereomicroscope (MZ75; Leica). Explants were placed 
on 0.1-µm nucleopore polycarbonate filters positioned on top of the metal 
grids and cultivated on the media/air interface. Immediately after isola-
tion, the explants were incubated in DME containing 10% FBS, GlutaMAX 
(Invitrogen), and primocin (InvivoGen) for 1 h, and then the media were re-
placed by DME containing 2× N2 supplement (Invitrogen), GlutaMAX, 
and primocin. Growth factor–soaked beads were placed in different posi-
tions on top of the explants under the stereomicroscope. In all experiments, 
beads treated with different growth factors were used for different explants 
produced from the same brain. Explants were cultivated in the CO2 incuba-
tor at 37°C for 56 h and then washed once with PBS and fixed in 4% PFA 
overnight at 4°C.JCB • VOLUME 192 • NUMBER 1 • 2011   168
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